ContextInfection with Epstein-Barr virus (EBV) has been associated with an increased risk of multiple sclerosis (MS), but the temporal relationship remains unclear.ObjectiveTo determine whether antibodies to EBV are elevated before the onset of MS.Design, Setting, and PopulationNested case-control study conducted among more than 3 million US military personnel with blood samples collected between 1988 and 2000 and stored in the Department of Defense Serum Repository. Cases were identified as individuals granted temporary or permanent disability because of MS. For each case (n = 83), 2 controls matched by age, sex, race/ethnicity, and dates of blood sample collection were selected.Main Outcome MeasuresAntibodies including IgA against EBV viral capsid antigen (VCA) and IgG against VCA, nuclear antigens (EBNA complex, EBNA-1, and EBNA-2), diffuse and restricted early antigens, and cytomegalovirus.ResultsThe average time between blood collection and MS onset was 4 years. The strongest predictors of MS were serum levels of IgG antibodies to VCA or EBNA complex. The risk of MS increased monotonically with these antibody titers; relative risk (RR) in persons in the highest category of VCA (≥2560) compared with those in the lowest (≤160) was 19.7 (95% confidence interval [CI], 2.2-174; Pfor trend = .004). For EBNA complex titers, the RR for those in the highest category (≥1280) was 33.9 (95% CI, 4.1-283; Pfor trend <.001) vs those in the lowest category (≤40). Similarly strong positive associations between EBV antibodies and risk of MS were already present in samples collected 5 or more years before MS onset. No association was found between cytomegalovirus antibodies and MS.ConclusionThese results suggest a relationship between EBV infection and development of MS.Elevations in anti–Epstein Barr virus (EBV) serum antibody titers occurring several years before diagnosis have been characteristically found in diseases probably caused by EBV, such as Burkitt lymphomaand nasopharyngeal carcinoma,and in Hodgkin disease.Anti-EBV antibodies are elevated in individuals with multiple sclerosis (MS),and we recently reported a premorbid increase in a small study,but it remains uncertain whether these elevations predate disease onset. We therefore conducted a larger prospective investigation using serial blood samples collected several years before onset of MS.METHODSStudy PopulationThe source population for the present study is more than 3 million US military personnel whose blood samples are stored at − 30°C in the Department of Defense Serum Repository.This repository contains more than 30 million serum specimens from active-duty and reserve personnel of the US military collected at entry and, on average, every 2 years thereafter since 1988. The research protocol was approved by the relevant institutional review board, which waived the need for consent to use blood products in a study.Case Ascertainment and Selection of ControlsCases were identified by searching the computerized database of the US Army Physical Disability Agency for active-duty personnel granted temporary or permanent disability because of MS and by reviewing medical records. We classified cases as definite MS if there was a history of 2 or more attacks, a diagnosis of MS made by a neurologist, and a positive magnetic resonance imaging (MRI) result or if the final diagnosis in the record was specified as definite MS, clinical definite MS, or laboratory-supported definite MS.Cases were classified as probable MS if they did not meet the criteria for definite MS but had at least 2 of the following: history of 2 or more attacks, positive MRI result, and diagnosis of MS made by a neurologist. These criteria (definite or probable MS) were met by 118 cases, 83 of whom had at least 1 serum sample collected before onset of MS symptoms (defined as the earliest neurological symptom ever reported) and were included in the study. For each of these 83 cases, we identified the earliest available serum sample (baseline sample) plus up to 2 additional samples collected before onset of MS and the first sample collected after onset of MS. For each of the 83 cases, we randomly selected 2 controls matched by age (±1 year), sex, race/ethnicity (white, black, Hispanic, or other), and dates of blood collection (±30 days). For serial samples, each blood sampling date was matched to within 30 days.Laboratory AnalysesSerum samples from MS cases and controls were sent to the laboratory in triplets containing the case and the 2 matched controls in random order without identification of case-control status. Immunoglobulin G and IgA antibodies to EBV viral capsid antigen (VCA) and anti–early antigen complex (diffuse [EA-D] and restricted [EA-R]) were determined by indirect immunofluorescence; IgG antibodies against the EBV nuclear antigen (EBNA) complex and 2 of its individual members, EBNA-1 and EBNA-2, were determined by anticomplement immunofluorescence.Immunoglobulin G antibody titers against cytomegalovirus (CMV) were also determined to assess the specificity of any association that may be found between MS and EBV serology.Statistical AnalysesGeometric mean antibody titers (reciprocal of the dilution) were compared between cases and controls using generalized linear models.We used conditional logistic regression to estimate the relative risk (RR) of MS associated with serum levels of specific antibody titers. The main regression analyses were conducted using the antibody titers as categorical variables; further analyses were conducted using the base 2 logarithm of the reciprocal of the dilution as a continuous variable (on this scale, a 1-unit increase corresponds to a 2-fold change in titers). Antibody titers were categorized by the highest dilution that tested positive, and each doubling (eg, 20, 40, 80) formed a category. The lowest and highest categories were collapsed because of small numbers or lack of cases in these categories. The differences in antibody titers between samples collected before or after MS onset were tested by paired ttest. All Pvalues are 2-tailed and significant at P<.05. We used SAS version 6.12 (SAS Institute Inc, Cary, NC) for all analyses.RESULTSBaseline characteristics of cases and controls are shown in Table 1. All cases and 96% of the controls had evidence of EBV infection (VCA IgG ≥20) at baseline (P= .08). For cases, the mean (SD) age at MS onset was 27 (5.5) years (range, 18-41 years). Certainty of diagnosis was definite in 53 (64%) and probable in 30 (36%). Mean (SD) time between baseline blood collection and MS onset was 4.0 (2.4) years (range, <1-11 years). The baseline geometric mean serum antibody titers to EBV were consistently higher among individuals who later developed MS than among their matched controls, whereas there was no difference in antibodies to CMV (Table 2). Similar results were observed in analyses restricted to cases with blood samples collected at least 5 years before the onset of MS (Table 2). The risk of MS increased monotonically with increasing serum levels of antibodies to VCA and EBNA complex. Compared with individuals with the lowest antibody titers, the RR was 19.7 (95% confidence interval [CI], 2.2-174; Pfor trend = .004) for individuals in the highest category of VCA IgG and was 33.9 (95% CI, 4.1-283; Pfor trend <.001) for individuals in the highest category of EBNA complex (Figure 1). A strong positive association was also found with EBNA-1 (RRs for titers from ≤40 to ≥1280: reference, 6.1, 8.1, 6.3, 11.9, and 16.7), whereas weaker associations were found for VCA IgA (RRs for titers ≤2.5, 10-20, and ≥40: reference, 0.0, and 3.6), EBNA-2 (RRs for titers from ≤2.5 to ≥160: reference, 1.4, 1.7, 3.1, 1.7, 3.1, and 2.5), EA-D (RRs for titers ≤2.5, 5-20, 40-80, and ≥160: reference, 0.7, 1.5, and 2.4), and EA-R (RRs for titers ≤2.5, 5-20, 40-80, and ≥160: reference, 2.3, 1.5, and 10.2). There was no association between antibodies to CMV and risk of MS (RRs for titers ≤5, 10-20, 40-80, and ≥160: reference, 2.3, 0.91, and 0.95).Table 1.Characteristics of Multiple Sclerosis Cases and ControlsCases (n = 83)Controls (n = 166)Sex, No. (%)Male54 (65)108 (65)Female29 (35)58 (35)Age at collection of baseline blood, yMean (SD)24 (5.1)24 (5.1)Range17-3917-39Race/ethnicity, No. (%)White50 (60)100 (60)Black29 (35)58 (35)Hispanic1 (1)2 (1)Other3 (4)6 (4)Education, No. (%)High school65 (78)127 (77)Some college7 (8)11 (7)Completed college7 (8)22 (13)Graduate school4 (5)6 (4)Table 2.Geometric Mean Titers of Antibodies in Baseline Serum SamplesAntibodiesAll SubjectsCases With Blood Collected ≥5 y Before MS OnsetCases (n = 83)Matched Controls (n = 165)*PValueCases (n = 28)Matched Controls (n = 56)PValueIgG to EBV VCA909603<.001840552.02IgA to EBV VCA3.02.8.26184.108.40.206EBNA complex537224<.001565197<.001EBNA-1385179<.001431147<.001EBNA-22617.022719.38Diffuse early antigen220.127.116.11.94.0.20Restricted early antigen4.13.2.065.43.2.02Cytomegalovirus1615.561416.65Abbreviations: EBNA, Epstein-Barr nuclear antigen; EBV, Epstein-Barr virus; MS, multiple sclerosis; VCA, viral capsid antigen.*Baseline antibody titers were missing for 1 control.Figure.Relative Risk of Multiple Sclerosis According to Anti-VCA IgG and Anti-EBNA Complex IgG Antibody Titers in Baseline Serum SamplesVCA indicates viral capsid antigen; IgG, immunoglobulin G; and EBNA, Epstein-Barr nuclear antigen. Asterisk indicates that baseline antibody titers were missing for 1 control.In analyses using the log-transformed antibody titers as continuous variables, strong associations were found with IgG antibodies to VCA, EBNA complex, and EBNA-1 (Table 3); these associations did not vary significantly by sex, age, or race/ethnicity. When the serum titers of different anti-EBV antibodies were included simultaneously in a regression model, only the EBNA complex and EBNA-1 titers retained statistical significance (these titers were not included at the same time because EBNA immunofluorescence is mostly accounted for by EBNA-1 antibodiesso that these titers are highly correlated). The EBNA-1/EBNA-2 ratio was not significantly associated with risk of MS. Results of analyses restricted to cases of definite MS were not materially different.Table 3.Relative Risk of MS Corresponding to a 4-Fold Increase in Anti-EBV and Anti-CMV Baseline Serum Antibody TitersAntibodiesAll Cases (n = 83)*Cases With Blood Collected ≥5 y Before MS Onset (n = 28)†RR (95% CI)PValueRR (95% CI)PValueIgG to EBV VCA1.8 (1.2-2.8)<.0011.9 (0.91-4.0).06IgA to EBV VCA1.4 (0.74-2.5).321.6 (0.62-4.1).33EBNA complex2.3 (1.6-3.4)<.0012.6 (1.3-5.0)<.001EBNA-11.7 (1.3-2.3)<.0012.2 (1.2-4.1).002EBNA-21.4 (1.1-1.9).021.3 (0.82-2.0).27Diffuse early antigen1.2 (0.89-1.7).221.2 (0.72-2.1).47Restricted early antigen1.5 (1.0-2.3).053.1 (1.1-8.8).008Cytomegalovirus1.1 (0.83-1.4).570.91 (0.53-1.6).72Abbreviations: CI, confidence interval; EBNA, Epstein-Barr nuclear antigen; EBV, Epstein-Barr virus; MS, multiple sclerosis; RR, relative risk; VCA, viral capsid antigen.*Conditional logistic regression: EBV and CMV titers were missing for 1 control (n = 165).†Conditional logistic regression: n = 56 controls.Finally, we used the repeated serological determinations to examine whether specific antibody titers varied among cases and whether there was evidence of EBV reactivation before onset of MS symptoms. For all antibodies, titers were similar in the earliest available sample (mean, 3.6 years before MS onset) and the sample collected after MS onset (mean, 1.0 years after MS onset). The geometric mean titers in the pre-onset and post-onset samples, respectively, were as follows: for VCA IgG, 905 and 896 (P= .88 by paired ttest); for VCA IgA, 3 and 3 (P= .32); for EBNA, 561 and 561 (P>.99); for EBNA-1, 400 and 405 (P= .92); for EBNA-2, 26 and 27 (P= .72); for EA-D, 4 and 4 (P= .76); for EA-R, 4 and 3 (P= .33); and for CMV, 18 and 17 (P= .68). Positive IgA titers to VCA and IgG titers to EA-D reflect repeated infection or reactivation. Overall, the proportion of cases and controls with at least 1 positive titer (≥5) before MS onset (index date in controls) was not significantly different in cases (6% for VCA IgA and 31% for EA-D) and controls (4% and 21%, respectively). However, cases were more likely than controls to have at least 1 sample with a titer of at least 80 (for VCA IgA, RR, 8.0; 95% CI, 1.3-50.4; P= .03; for EA-D, RR, 4.2; 95% CI, 1.6-11.4; P= .005).COMMENTThese results confirm those obtained in a smaller study of women with MS.Although the date of onset of MS is difficult to establish accurately, and many patients at the time of clinical onset have multiple silent MRI lesions,the lack of variation in our study in anti-EBV antibody titers between samples collected 6 to 11 years before the estimated MS onset and later samples suggests that the increased antibody response to EBV occurs early in relation to the pathological process that leads to demyelination and clinical disease. Furthermore, all cases were already seropositive at the time of collection of the first blood sample (mean, 4 years before MS onset) and appeared to have stable antibody titers, suggesting that there is a long lag time between infection with EBV and occurrence of MS.The pattern of antibody response that we observed among individuals who developed MS is different from the pattern observed in immunocompromised hosts or in chronic infectious mononucleosis, where there are elevated anti–EBNA-2 and reduced anti–EBNA-1 titers,and from that observed in Burkitt lymphoma, where there are prediagnostic elevations of anti-VCA but not anti-EBNA antibodies.Rather, the simultaneous elevation of titers to VCA and EBNA-1 suggests a more severe or more recent primary infection or reactivation of infection accompanied by a vigorous cellular immune response.A similar pattern of anti-VCA and anti-EBNA IgG elevation in prediagnostic sera has been associated with risk of Hodgkin diseaseand nasopharyngeal carcinoma,but in the latter the strongest predictors of risk are IgA antibodies to VCA.As previously discussed, these results support a role for EBV in the etiology of MS.Gde-TheAGeserNEDayEpidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study.Nature.1978;274:756-761.ABRickinsonEKieffEpstein-Barr virus.In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. Philadelphia, Pa: Lippincott-Raven; 1996:2397-2446.NMuellerAEvansNLHarrisHodgkin's disease and Epstein-Barr virus: altered antibody pattern before diagnosis.N Engl J Med.1989;320:689-695.PDLarsenLCBloomerPFBrayEpstein-Barr nuclear antigen and viral capsid antigen antibody titers in multiple sclerosis.Neurology.1985;35:435-438.PVShirodariaMHaireEFlemingViral antibody titers: comparison in patients with multiple sclerosis and rheumatoid arthritis.Arch Neurol.1987;44:1237-1241.AAscherioKLMungerETLennetteEpstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study.JAMA.2001;286:3083-3088.MVRubertoneJFBrundageThe defense medical surveillance system and the Department of Defense Serum Repository: glimpses of the future of comprehensive public health surveillance.Am J Public Health.2002;92:1900-1904.CPoserDPatyLScheinbergNew diagnostic criteria for multiple sclerosis.Ann Neurol.1983;13:227-231.WHenleGHenleJAnderssonAntibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection.Proc Natl Acad Sci U S A.1987;84:570-574.ETLennetteEpstein-Barr virus.In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology. 7th ed. Washington, DC: ASM Press; 1999:912-918.ETLennetteLRymoMYadavGMasucciKMerkLTimarGKleinDisease-related differences in antibody patterns against EBV-encoded nuclear antigens EBNA 1, EBNA 2 and EBNA 6.Eur J Cancer.1993;29A:1584-1589.ELennetteDLennetteImmune adherence hemagglutination.In: Specter S, Hodinka R, Young S, eds. Clinical Virology Manual.Washington, DC: ASM Press; 2000:140-145.PDiggleKLiangSZegerAnalysis of Longitudinal Data.Oxford, England: Clarendon Press; 1994:253.PABrexJIO'RiodanKAMiszkielMultisequence MRI in clinically isolated syndromes and the early development of MS.Neurology.1999;53:1184-1190.WHenleGHenleJCNiedermanEKlemolaKHaltiaAntibodies to early antigens induced by Epstein-Barr virus in infectious mononucleosis.J Infect Dis.1971;124:58-67.YKusunokiHHuangYFukudaA positive correlation between the precursor frequency of cytotoxic lymphocytes to autologous Epstein-Barr virus-transformed B cells and antibody titer level against Epstein-Barr virus-associated nuclear antigen in healthy seropositive individuals.Microbiol Immunol.1993;37:461-469.CAHorwitzWHenleGHenleLong-term serological follow-up of patients for Epstein-Barr virus after recovery from infectious mononucleosis.J Infect Dis.1985;151:1150-1153.Gde-TheEpidemiology of Epstein-Barr virus and associated diseases in man.In: Roizman B, ed. The Herpesviruses. Vol 1. New York, NY: Plenum Press; 1982:25-103.YCChienJYChenMYLiuSerologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men.N Engl J Med.2001;345:1877-1882.Corresponding Author and Reprints:Alberto Ascherio, MD, DrPH, Harvard School of Public Health, Nutrition Department, 665 Huntington Ave, Boston, MA 02115 (e-mail: Alberto.Ascherio@channing.harvard.edu).Author Contributions:Study concept and design:Levin, Rubertone, Spiegelman, Ascherio.Acquisition of data:Munger, Rubertone, Peck, Lennette, Spiegelman, Ascherio.Analysis and interpretation of data:Levin, Munger, Peck, Spiegelman, Ascherio.Drafting of the manuscript:Levin, Rubertone, Ascherio.Critical revision of the manuscript for important intellectual content:Levin, Munger, Peck, Lennette, Spiegelman, Ascherio.Statistical expertise:Levin, Spiegelman, Ascherio.Obtained funding:Spiegelman, Ascherio.Administrative, technical, or material support:Levin, Munger, Rubertone, Peck, Lennette, Spiegelman, Ascherio.Study supervision:Peck, Spiegelman, Ascherio.Funding/Support:This study was supported by grant NS42194 from the National Institute of Neurological Disorders and Stroke. Preliminary work was supported by a pilot grant from the National Multiple Sclerosis Society.Disclaimer:The views expressed are those of the authors and should not be construed to represent the positions of the Department of the Army or Department of Defense.Acknowledgment:We thank Walter Willett, MD, DrPH, and Nancy Mueller, ScD, for their expert advice and Eilis O'Reilly, MSc, and Elsa Jiménez for technical assistance.
JAMA – American Medical Association
Published: Mar 26, 2003